Last updated: August 26, 2026
Griseofulvin ultramicrosize is a mature, low-revenue oral antifungal product with limited growth potential. The market is driven by generic substitution, intermittent prescribing, and competition from terbinafine and newer topical or systemic antifungals. The branded product Gris-PEG has no meaningful remaining composition-of-matter exclusivity, and publicly available regulatory information does not indicate a material active patent barrier to generic entry. Financial performance is likely stable to declining in nominal terms, with value concentrated in manufacturing efficiency, reliable supply, and niche channel access rather than price expansion.
What is griseofulvin ultramicrosize used for?
Griseofulvin ultramicrosize is an oral antifungal indicated for dermatophyte infections involving the skin, hair, and nails. It is used when topical treatment is inadequate or impractical. The ultramicrosize formulation improves absorption relative to conventional microsize griseofulvin and permits lower milligram dosing.
The product is marketed in the United States primarily as Gris-PEG and through generic equivalents. The reference product is an oral tablet available in 125 mg and 250 mg strengths. Treatment duration varies by infection site and organism, with scalp and nail infections generally requiring longer treatment than uncomplicated skin infections.
Griseofulvin is not indicated for Candida infections or systemic fungal infections. Its clinical use is concentrated in dermatology, pediatrics, primary care, and selected infectious-disease settings.
What are the key product characteristics?
| Attribute |
Griseofulvin ultramicrosize |
| Active ingredient |
Griseofulvin |
| Dosage form |
Oral tablet |
| Common strengths |
125 mg and 250 mg |
| Product type |
Small-molecule drug |
| FDA pathway |
Original NDA and generic ANDAs |
| Main therapeutic area |
Dermatophyte infections |
| Primary branded product |
Gris-PEG |
| Biosimilar exposure |
None |
| Current market structure |
Mature branded-generic market |
| Principal competitors |
Terbinafine, itraconazole, fluconazole, topical antifungals |
The product has a long clinical history and faces limited innovation-driven demand. Prescribers often choose alternative agents based on shorter treatment courses, broader activity, fewer administration constraints, or better evidence for particular infection types.
How large is the griseofulvin ultramicrosize market?
The U.S. griseofulvin market is a small generic pharmaceutical segment. Public companies generally do not report griseofulvin ultramicrosize revenue separately, and standalone product sales estimates are not consistently available in public filings. The commercial market is best characterized as low-revenue and mature rather than as a growth pharmaceutical category.
Market demand is constrained by four factors:
- Dermatophyte infections are often treated topically.
- Oral prescribing is episodic rather than chronic.
- Generic substitution limits net pricing.
- Terbinafine and azole antifungals have displaced some griseofulvin use.
Demand remains durable in pediatric tinea capitis, where griseofulvin retains clinical familiarity and is often used when treatment duration, tolerability, and pediatric experience are prioritized. The product also remains relevant where local resistance patterns, contraindications, age considerations, or formulary status favor griseofulvin.
What drives revenue for griseofulvin ultramicrosize?
Revenue is primarily determined by prescription volume, generic penetration, payer reimbursement, and manufacturing availability. Price increases can occur in small generic markets when supply is concentrated, but those increases are vulnerable to substitution and payer intervention.
A simplified commercial model is:
| Revenue driver |
Directional effect |
| Pediatric tinea capitis prescribing |
Supports demand |
| Generic substitution |
Reduces branded revenue |
| Terbinafine adoption |
Reduces volume |
| Limited supplier base |
Can support pricing |
| Short-term shortages |
Can increase sales for available suppliers |
| Retail pharmacy reimbursement |
Compresses margins |
| Hospital and Medicaid purchasing |
Increases price sensitivity |
| New clinical indications |
No established near-term driver |
Griseofulvin does not have the profile of a specialty product with recurring high-value revenue. It is usually dispensed as a low-cost acute or short-course prescription. The commercial value of a product portfolio depends more on aggregate generic volume than on this molecule alone.
What is the financial trajectory for griseofulvin ultramicrosize?
The expected financial trajectory is flat to declining revenue with periodic volatility caused by supply disruptions, manufacturer exits, and reimbursement changes.
Base case
The base case is gradual unit decline and continuing price compression. Generic competition and alternative antifungals limit the ability to sustain premium pricing. The branded product may retain a small demand base among physicians and pharmacies that prefer an established source, but the addressable market is narrow.
Upside case
An upside scenario would require a temporary shortage, competitor withdrawal, a manufacturing disruption affecting alternative antifungals, or a meaningful increase in pediatric oral antifungal prescribing. These events could improve short-term volume or net price but would not create durable category growth.
Downside case
The downside case involves additional generic entrants, reduced pediatric use, greater adoption of terbinafine or alternative azoles, formulary exclusion, or discontinuation of the branded product. A manufacturer with high fixed costs or a small production run could experience margin pressure even if prescription volume remains stable.
| Period |
Expected commercial condition |
| Historical period |
Branded product transitioned to mature generic competition |
| Current period |
Low-value, established demand with limited innovation |
| Near term |
Stable-to-declining volume; episodic pricing volatility |
| Medium term |
Continued generic erosion and therapeutic substitution |
| Long term |
Residual niche demand, subject to product availability |
No credible public basis supports a high-growth revenue forecast for griseofulvin ultramicrosize. Any investment thesis would depend on manufacturing economics, supply reliability, portfolio bundling, or temporary market concentration.
When does griseofulvin ultramicrosize lose exclusivity?
Griseofulvin ultramicrosize lost meaningful exclusivity decades ago. The active ingredient is an established small molecule, and the original product patents and regulatory exclusivities are long expired.
The reference product's U.S. regulatory history includes Gris-PEG under NDA 018226. Generic manufacturers can seek approval through abbreviated new drug applications by demonstrating pharmaceutical equivalence and bioequivalence under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Original composition-of-matter patents |
Expired |
| Pediatric exclusivity |
No material current protection identified |
| Orphan-drug exclusivity |
Not applicable |
| New formulation exclusivity |
No material current protection identified |
| Biosimilar exclusivity |
Not applicable |
| Generic entry pathway |
ANDA approval |
FDA's Orange Book lists approved drug products, therapeutic equivalence information, and patents submitted by sponsors. Griseofulvin ultramicrosize is a conventional genericized small-molecule product rather than a product protected by a current biologic or specialty-drug exclusivity regime. [1]
What patents protect griseofulvin ultramicrosize?
No commercially meaningful active patent estate is publicly evident for the underlying griseofulvin molecule or the historical ultramicrosize product. Any legacy patents covering the active ingredient, particle size, formulation, or original product development are expected to have expired.
Potential patent categories include:
- Composition-of-matter patents for griseofulvin.
- Particle-size or micronization patents.
- Tablet formulation patents.
- Manufacturing-process patents.
- Method-of-use patents for fungal infections.
The practical market risk is not patent infringement. It is regulatory approval, product quality, supply continuity, and commercial competition. A company entering the market would usually face an abbreviated approval process rather than a Paragraph IV patent challenge strategy.
Are formulation patents relevant?
Formulation patents could theoretically cover particle-size distributions, excipient systems, dissolution behavior, or manufacturing methods. In practice, the ultramicrosize concept is old and has been commercially deployed for many years. A new entrant may still need to establish bioequivalence and manufacturing consistency, but those requirements are regulatory and technical barriers, not evidence of a durable exclusivity position.
A formulation-specific patent could matter if it were unexpired, listed in the Orange Book, and difficult to design around. Publicly available product information does not indicate that such a patent currently controls the commercial market for griseofulvin ultramicrosize.
Are there Paragraph IV challenges to Gris-PEG?
There is no widely reported current Paragraph IV litigation affecting Gris-PEG that creates a material barrier to generic entry. Because the product is long off patent, generic manufacturers would generally not need to challenge a live patent to enter the market.
Paragraph IV litigation is more relevant where a reference product has unexpired Orange Book-listed patents. For griseofulvin ultramicrosize, the economic question is whether an ANDA applicant can manufacture a bioequivalent product at an acceptable cost, not whether it can overcome a current patent thicket.
A future Paragraph IV filing would require a newly listed patent or an unusual patent assertion. That is not the normal commercial profile of this product.
What is the FDA regulatory and Orange Book status?
Griseofulvin ultramicrosize is an FDA-approved prescription drug. The branded reference product is associated with NDA 018226, while generic versions are approved through ANDAs.
The relevant regulatory issues are:
- Demonstration of bioequivalence to the reference product.
- Compliance with current good manufacturing practice requirements.
- Control of particle size and dissolution characteristics.
- Stability across the labeled shelf life.
- Accurate labeling for pediatric and adult dosing.
- Ongoing compliance with FDA post-approval requirements.
The Orange Book is the authoritative source for current reference-product designation, therapeutic equivalence codes, and listed patents. The commercial status of individual generic products can change through approval, discontinuation, or manufacturer updates. [1]
What regulatory barriers affect new manufacturers?
The principal barriers are technical and economic:
- Reproducing the ultramicrosize formulation consistently.
- Demonstrating bioequivalence.
- Maintaining validated manufacturing controls.
- Securing an API supply that meets quality specifications.
- Achieving sufficient scale to offset filing and commercial costs.
These barriers can reduce the number of active suppliers even when no patent barrier exists. That creates occasional supply-based pricing power, but the opportunity is generally limited by low market demand.
Which companies compete with griseofulvin ultramicrosize?
Competition exists at two levels: products containing griseofulvin and alternative antifungal therapies.
Direct competition
Direct competitors include the Gris-PEG brand and approved generic griseofulvin ultramicrosize tablets. Other griseofulvin products, including microsize formulations or oral suspensions where available, compete for the same prescriptions but may not be dose-equivalent on a milligram basis.
Therapeutic competition
| Competitor |
Main commercial advantage |
| Terbinafine |
Often shorter treatment courses and strong activity against dermatophytes |
| Itraconazole |
Broader antifungal activity |
| Fluconazole |
Familiar dosing and broad prescribing base |
| Topical terbinafine |
Convenient treatment for selected superficial infections |
| Topical azoles |
Low cost and broad retail availability |
| Ciclopirox and related agents |
Topical alternatives for localized disease |
Griseofulvin retains a role in tinea capitis, particularly in pediatric practice. It is less competitive where shorter treatment duration or broader organism coverage is important.
What licensing deals affect griseofulvin ultramicrosize?
No major current licensing transaction is publicly associated with griseofulvin ultramicrosize. The product is a mature generic medicine, and commercial rights are generally handled through manufacturing, distribution, private-label, or supply agreements rather than high-value originator licensing.
Potential deal structures include:
- Contract manufacturing.
- Private-label supply to pharmacy or wholesale companies.
- Regional distribution agreements.
- Portfolio acquisitions involving multiple generic products.
- API supply agreements.
The absence of a major licensing market is consistent with the product's low revenue potential and expired core intellectual property.
What litigation affects griseofulvin ultramicrosize?
No material current patent litigation is widely associated with the product. Litigation exposure is more likely to arise from:
- Product liability claims.
- Manufacturing-quality disputes.
- Contract and supply disagreements.
- False advertising or labeling allegations.
- Regulatory enforcement unrelated to patent exclusivity.
The product's mature status lowers ANDA litigation risk but does not eliminate operational or compliance risk. A manufacturer with a concentrated supply chain could face commercial losses from an FDA warning letter, manufacturing hold, recall, or API disruption.
How strong is the patent estate for griseofulvin ultramicrosize?
The patent estate is weak from an exclusivity perspective. Its principal strengths are historical formulation know-how, manufacturing experience, regulatory files, and brand recognition rather than enforceable patent rights.
| Patent-estate factor |
Assessment |
| Molecule protection |
Expired |
| Product-specific exclusivity |
Expired |
| Active Orange Book protection |
No material protection identified |
| Formulation differentiation |
Technically relevant but historically mature |
| Manufacturing know-how |
Potentially useful, generally nonexclusive |
| Litigation leverage |
Low |
| Generic entry risk |
High |
| Pricing protection |
Low |
For an acquirer, the asset should be valued as a mature commercial product, not as an intellectual-property-protected pharmaceutical.
What generic launch scenarios exist?
A new generic entrant could pursue several launch strategies:
Standard ANDA launch
The most likely strategy is an ANDA for a tablet strength matching the reference product, followed by launch at a discount to the branded product. This would increase price pressure and reduce the value of the branded franchise.
Limited-competition launch
If few manufacturers remain active, a new entrant could achieve reasonable volume despite the small market. The opportunity would depend on low manufacturing costs and access to wholesalers, Medicaid channels, and retail pharmacy networks.
Shortage-driven launch
A supplier could enter or expand during a shortage affecting Gris-PEG or other generic suppliers. This could produce temporary pricing gains, but competitors would likely respond if the shortage persisted.
Portfolio-based launch
The strongest commercial rationale is likely bundling griseofulvin with other dermatology or pediatric generics. A standalone launch would face higher sales and distribution costs relative to expected revenue.
What geographic markets matter?
The United States is a mature, price-sensitive market. International demand varies with public-health access, dermatophyte prevalence, generic procurement systems, and availability of newer antifungals.
Emerging-market demand may be supported by:
- High prevalence of superficial fungal infections.
- Lower access to newer antifungals.
- Public-sector procurement of established medicines.
- Local manufacturing incentives.
International expansion would face country-specific registration requirements, local bioequivalence rules, tender pricing, and distribution barriers. The absence of patent protection generally facilitates entry but also increases price competition.
Key Takeaways
- Griseofulvin ultramicrosize is a mature, low-revenue generic pharmaceutical market.
- Gris-PEG and generic products compete mainly in pediatric and dermatology indications.
- Core patent and regulatory exclusivity rights expired long ago.
- No material current patent estate or widely reported Paragraph IV litigation is evident.
- FDA approval depends on bioequivalence, formulation consistency, and manufacturing compliance.
- Terbinafine, itraconazole, fluconazole, and topical antifungals limit market growth.
- Revenue is likely stable to declining, with temporary volatility from shortages or supplier exits.
- Commercial value lies in low-cost manufacturing, supply reliability, and portfolio distribution.
- Biosimilar risk does not apply because griseofulvin is a conventional small-molecule drug.
- A standalone investment thesis is weak unless supported by supply concentration or portfolio synergies.
FAQs
Is griseofulvin ultramicrosize still commercially available?
Yes. Gris-PEG and generic griseofulvin ultramicrosize products have been marketed in the United States, although product availability can vary by manufacturer, wholesaler, and pharmacy.
Is Gris-PEG more valuable than generic griseofulvin?
The brand may retain limited value through recognition, sourcing continuity, or prescriber preference, but its pricing power is constrained by long-established generic competition.
Can a company obtain market exclusivity for a new griseofulvin formulation?
A genuinely novel formulation could potentially qualify for patent protection or regulatory exclusivity, but the underlying drug would not receive new chemical entity exclusivity. Any protection would depend on demonstrable novelty, non-obviousness, and product-specific regulatory eligibility.
Does griseofulvin ultramicrosize face generic substitution?
Yes. Generic substitution is a central feature of the market. Therapeutic-equivalence designations and payer policies can determine whether pharmacies dispense generic products instead of Gris-PEG.
What is the primary investment risk for a griseofulvin manufacturer?
The primary risk is inadequate margin at low market volume. Supply disruptions can create temporary upside, but long-term returns depend on manufacturing efficiency, regulatory compliance, and the ability to distribute the product economically.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. National Library of Medicine. (2024). DailyMed: Gris-PEG (griseofulvin ultramicrosize) tablet labeling. https://dailymed.nlm.nih.gov/
- U.S. Food and Drug Administration. (2024). Generic drug facts. https://www.fda.gov/drugs/generic-drugs
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application ANDA approvals. https://www.fda.gov/drugs/generic-drugs/generic-drug-approval-process
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
